3.80

3.83% 0.14

Pre-market: 3.80

Goodrx Holdings Inc (GDRX)

Overview News Price History Option Chain Financials Why GDRX Down? Discussions Forecast

Goodrx Holdings Inc stock is traded at $3.80, with a volume of 1.92M. It is up +3.83% in the last 24 hours and up +28.81% over the past month. GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.

Previous Close:

$3.66

Open:

$3.67

24h Volume:

1.92M

Relative Volume:

1.29

Market Cap:

$1.29B

Revenue:

$787.89M

Net Income/Loss:

$20.56M

P/E Ratio:

64.96

EPS:

0.0585

Net Cash Flow:

$96.54M

1W Performance:

+13.77%

1M Performance:

+28.81%

6M Performance:

+70.40%

1Y Performance:

+9.20%

1-Day Range:

$3.665

$3.89

1-Week Range:

$3.215

$3.89

52-Week Range:

$1.77

$5.8099

Goodrx Holdings Inc Stock (GDRX) Company Profile

Name

Goodrx Holdings Inc

Sector

Healthcare (1079)

Industry

Health Information Services (48)

Phone

(855) 268-2822

Address

2701 OLYMPIC BOULEVARD, SANTA MONICA

Employee

697

Twitter

Next Earnings Date

2026-08-05

Latest SEC Filings

GDRX's Discussions on Twitter

Compare GDRX vs VEEV, BTSG, TEM, HQY, TXG

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GDRX Goodrx Holdings Inc	3.80	1.03B	787.89M	20.56M	96.54M	0.0585
VEEV Veeva Systems Inc	236.58	31.59B	3.32B	941.65M	1.64B	5.6161
BTSG Brightspring Health Services Inc	57.89	14.13B	13.65B	169.86M	412.12M	1.0758
TEM Tempus Ai Inc	55.69	7.73B	1.36B	-302.91M	-219.93M	-1.7182
HQY Healthequity Inc	105.57	8.28B	1.34B	230.70M	440.96M	2.6695
TXG 10 X Genomics Inc	58.48	5.83B	638.78M	-22.66M	122.18M	-0.1744

Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-27-26	Downgrade	JP Morgan	Overweight → Neutral
Jan-22-26	Downgrade	Jefferies	Buy → Hold
Dec-09-25	Initiated	Barclays	Underweight
Aug-11-25	Downgrade	Raymond James	Strong Buy → Outperform
Dec-04-24	Initiated	Mizuho	Neutral
Aug-09-24	Upgrade	Raymond James	Outperform → Strong Buy
May-23-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
May-16-24	Upgrade	Raymond James	Mkt Perform → Outperform
Apr-10-24	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Mar-25-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Mar-01-24	Upgrade	JP Morgan	Neutral → Overweight
Feb-26-24	Initiated	Leerink Partners	Outperform
Jan-02-24	Downgrade	BofA Securities	Buy → Underperform
Aug-10-23	Upgrade	DA Davidson	Neutral → Buy
Jul-31-23	Upgrade	TD Cowen	Market Perform → Outperform
Dec-01-22	Initiated	Citigroup	Buy
Nov-04-22	Upgrade	JP Morgan	Underweight → Neutral
Sep-16-22	Initiated	KeyBanc Capital Markets	Sector Weight
Sep-07-22	Initiated	Truist	Hold
Aug-12-22	Initiated	DA Davidson	Neutral
Jun-10-22	Downgrade	Goldman	Buy → Neutral
Jun-06-22	Resumed	BofA Securities	Buy
Jun-01-22	Downgrade	Robert W. Baird	Outperform → Neutral
May-10-22	Downgrade	Evercore ISI	Outperform → In-line
May-10-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
May-10-22	Downgrade	Raymond James	Outperform → Mkt Perform
May-10-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Apr-11-22	Initiated	Wells Fargo	Equal Weight
Apr-07-22	Initiated	Guggenheim	Buy
Apr-01-22	Resumed	Credit Suisse	Neutral
Mar-15-22	Upgrade	Robert W. Baird	Neutral → Outperform
Mar-01-22	Reiterated	Barclays	Overweight
Mar-01-22	Reiterated	BofA Securities	Neutral
Mar-01-22	Downgrade	Cowen	Outperform → Market Perform
Mar-01-22	Downgrade	Credit Suisse	Outperform → Neutral
Mar-01-22	Reiterated	Evercore ISI	Outperform
Mar-01-22	Reiterated	Goldman	Buy
Mar-01-22	Reiterated	JP Morgan	Underweight
Mar-01-22	Reiterated	RBC Capital Mkts	Outperform
Mar-01-22	Reiterated	SVB Leerink	Outperform
Jan-07-22	Initiated	Goldman	Buy
Dec-21-21	Initiated	Stephens	Overweight
Dec-02-21	Initiated	Jefferies	Buy
Aug-31-21	Upgrade	Barclays	Equal Weight → Overweight
Aug-13-21	Upgrade	Raymond James	Mkt Perform → Outperform
May-28-21	Initiated	Robert W. Baird	Neutral
Apr-06-21	Resumed	Evercore ISI	Outperform
Jan-25-21	Initiated	Guggenheim	Buy
Nov-19-20	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Nov-18-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-19-20	Initiated	Barclays	Equal Weight
Oct-19-20	Initiated	BofA Securities	Neutral
Oct-19-20	Initiated	Citigroup	Buy
Oct-19-20	Initiated	Cowen	Outperform
Oct-19-20	Initiated	Credit Suisse	Outperform
Oct-19-20	Initiated	Deutsche Bank	Hold
Oct-19-20	Initiated	Goldman	Neutral
Oct-19-20	Initiated	JP Morgan	Neutral
Oct-19-20	Initiated	Morgan Stanley	Overweight
Oct-19-20	Initiated	RBC Capital Mkts	Sector Perform
Oct-19-20	Initiated	SVB Leerink	Outperform
Oct-19-20	Initiated	UBS	Buy

View All

Goodrx Holdings Inc Stock (GDRX) Latest News

06:00 AM

GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope (NASDAQ:GDRX) - Seeking Alpha

06:00 AM

Aug 11, 2026

GDRX Maintained by Citigroup -- Price Target Raised to $5.00 - GuruFocus

Aug 11, 2026

GoodRx (NASDAQ:GDRX) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat

Aug 11, 2026

GDRX Maintained by TD Cowen -- Price Target Raised to $5.00 - GuruFocus

Aug 11, 2026

GDRX Q2 Deep Dive: Pharma Direct and Subscription Growth Drive Upgraded Outlook - Yahoo Finance UK

Aug 11, 2026

GOODRX HOLDINGS, INC. : CITIGROUP RAISES TARGET PRICE TO $5 FROM $4 - Bitget

Aug 11, 2026

Aug 07, 2026

GDRX Maintains Overweight by Wells Fargo -- Price Target Raised to $5.00 - GuruFocus

Aug 07, 2026

GoodRx Holdings Price Target Raised to $5.00/Share From $3.50 by Wells Fargo - moomoo.com

Aug 07, 2026

Prescription savings giant GoodRx could be opening office at The Pearl - The Business Journals

Aug 07, 2026

Wells Fargo & Company Boosts GoodRx (NASDAQ:GDRX) Price Target to $5.00 - MarketBeat

Aug 07, 2026

GoodRx Holdings, Inc. Stock 12‑Month Price Target Raised to $3.7 - TradingView

Aug 07, 2026

Morgan Stanley Adjusts Price Target on GoodRx to $4 From $3, Maintains Equalweight Rating - marketscreener.com

Aug 07, 2026

GoodRx (GDRX) Stock Jumps As Margins Strengthen And User Declines Linger - Sahm

Aug 07, 2026

Earnings call transcript: GoodRx lifts 2026 outlook after Q2 revenue beat - Investing.com Canada

Aug 07, 2026

Aug 06, 2026

Transcript : GoodRx Holdings, Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com

Aug 06, 2026

GoodRx Lets Customers Shop Where They Want, CEO Says - marketscreener.com

Aug 06, 2026

GoodRx Q2 Earnings Call Highlights - MarketBeat

Aug 06, 2026

GoodRx (NASDAQ:GDRX) Stock Price Up 15.7%Here's Why - MarketBeat

Aug 06, 2026

GDRX: Pharma Direct and subscriptions drove Q2 outperformance, leading to raised 2026 guidance - TradingView

Aug 06, 2026

GoodRx Holdings, Inc. Q2 2026 Earnings Call Summary - finance.yahoo.com

Aug 06, 2026

GDRX Looks 42.2% Undervalued on GF Value™ - GuruFocus

Aug 06, 2026

GDRX SWOT Analysis: Key Insights from the 10-Q Filing - GuruFocus

Aug 06, 2026

Aug 05, 2026

GoodRx (NASDAQ:GDRX) Posts Earnings Results, Hits Estimates - MarketBeat

Aug 05, 2026